Increasing Number Of Bispecific Antibody Clinical Trials Based On Proprietary Technologies Developed By Local Pharmaceutical Companies Driving The Chinese Bispecific Antibody market
China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- China Bispecific Antibodies Market Sales Opportunity To Double By 2028
- 3 to 4 Bispecific Antibodies Are Further Expected To Enter the Market Over Next 5 Years
- Comprehensive Insight On Ongoing Bispecific Antibodies Clinical Trials By Phase, Company, Indication & Patient Segment
- Bispecific Antibodies Trials In China: > 250 Antibodies
- Comprehensive Insight On More Than 80 Bispecific Antibodies Available For Licensing/Partnership
- China Bispecific Antibodies Market Dynamics
- Insight On Key Chinese Companies Developing Bispecific Antibodies
Download Report Sample:
For a long time, conventional methods like surgery, radiotherapy and chemotherapy have dominated the therapeutic segment for cancer treatment. These methods are efficient in treating cancer but are also associated with severe side-effects which make the patients apprehensive to undergo any of the traditionally used methods. This drawback has encouraged scientists to explore and develop newer, targeted approaches like immunotherapy to destroy cancer cells. Out of all immunotherapy approaches, bispecific antibodies have gained the most interest in recent times because of its mode of action.
Bispecific antibodies use the body’s own immune cells to fight cancerous cells. It is a form of targeted therapy whose benefits greatly outweighs the side-effects it causes which is why it has grabbed a lot of attention from Chinese and international researchers alike. The technology used to develop these is constantly evolving with regional researchers leaving no opportunity to move ahead in the global scenario. The global bispecific antibodies R&D pipeline is packed with currently over 800 antibodies in ongoing clinical trials. China comes second to US in being the most preferred location for hosting these trials with more than 250 antibodies in progress.
China is also seeing a rise in the number of partnerships between domestic and western pharmaceutical companies driven by positive and commercially successful outcomes of already available bispecific antibodies in the market. These partnerships are centered on clinical development and/or commercializing the drugs in Chinese as well as the international market. BLINCYTO, which was the first bispecific antibody to gain approval globally, was developed by Amgen and was commercialized in China by BeiGene under an agreement between the two companies. Additionally, Hemlibra (Roche) was the very first bispecific antibodies to gain market approval in China. With the approval of another bispecific antibody in 2022, the number of bispecific antibodies approved in China has increased to 3 while the global count is now 8.
The technological advances and the introduction of sophisticated machinery at different phases of the development process are some of the key factors driving the increase in the drugs in pipeline and the number of bispecific antibodies that are becoming commercially available. Chinese companies have developed a number of them in the past four to five years, including various platforms like YBODY®, CRIBTM, ITabTM, and FIT-Ig that make the discovery of bispecific antibodies easier than the techniques previously employed. With the help of these innovative technologies, numerous pharma companies have partnered up to co-develop bispecific antibodies. One such instance of a strategic alliance was that between the US-based pharmaceutical business Abpro and the China-based company NJCTTQ, which allowed the two to make use of the former’s proprietary DiversImmune technology to create bispecific antibodies. In accordance with their agreement, NJCTTQ will gain the rights in China for all produced bispecific antibodies, while Abpro will benefit from market sales from the rest of the world, excluding Thailand. Another illustration is how EpimAb has recently been at the centre of numerous collaborations with both domestic and foreign companies, granting them access to their unique proprietary bispecific antibody development platform known as FIT-Ig. The positive outcomes of these partnerships will encourage more collaborations, which can help fill the clinical pipeline.
The policies of the Chinese government are slowly evolving to allow the expansion of western pharmaceutical firms operating in the country. They have adequately gathered that the investments and expertise brought by foreign scientists will support the expansion of the market for bispecific antibodies, which will benefit the entire pharmaceutical industry. Both domestic and foreign pharmaceutical businesses operating in the region now have access to sufficient incentives thanks to the new regulatory framework and regulations, including tax breaks, VAT exemptions, and other benefits related to the location of their facilities.
Because of its extensive clinical pipeline, the bispecific antibodies market in China is anticipated to expand substantially within the next few years. Numerous medications created both within and outside of China are now being investigated in the country. This, in addition to the new pharmaceutical regulations, will encourage the participation of more foreign companies and will bring in investments, helping China to establish its presence in the global pharmaceutical industry.